Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lecankitug Injection - Kanova Biopharmaceutical/Livzon Pharmaceutical

Next Previous
Drug Profile

Lecankitug Injection - Kanova Biopharmaceutical/Livzon Pharmaceutical

Alternative Names: LZM-012; XKH-004

Latest Information Update: 03 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kanova Biopharmaceutical
  • Developer Kanova Biopharmaceutical; Livzon Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Plaque psoriasis
  • Phase III Ankylosing spondylitis

Most Recent Events

  • 27 Aug 2026 Registered for Plaque psoriasis in China (SC) - First global approval
  • 26 Jan 2026 Livzon Pharmaceuticals completes a phase III trial in Plaque psoriasis in China (SC) (NCT07746479)
  • 14 Nov 2025 Kanova Biopharmaceutical completes a phase III trial in Ankylosing spondylitis (Treatment-experienced) in China (SC) (NCT07498634)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top